Literature DB >> 11006528

Secretases as targets for the treatment of Alzheimer's disease.

M Citron1.   

Abstract

Alzheimer's disease (AD) is the major cause of dementia in most developed countries. Treatment to modify this disease is currently unavailable, but needed urgently. The amyloid-cascade hypothesis proposes that amyloid beta-peptide (Abeta), found in the plaques characteristic of AD, plays an early, critical role in the disease process. It follows that preventing the generation of Abeta could be therapeutically useful in all cases of AD. Inhibition of the secretases that produce Abeta from a large precursor protein is the main approach to achieve this goal.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006528     DOI: 10.1016/s1357-4310(00)01759-7

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  11 in total

Review 1.  In vivo amyloid imaging in Alzheimer's disease.

Authors:  H I Sair; P M Doraiswamy; J R Petrella
Journal:  Neuroradiology       Date:  2004-01-23       Impact factor: 2.804

2.  Mass spectrometry-based screening for inhibitors of beta-amyloid protein aggregation.

Authors:  Xun Cheng; Richard B van Breemen
Journal:  Anal Chem       Date:  2005-11-01       Impact factor: 6.986

Review 3.  Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease.

Authors:  Fernanda G De Felice; Sérgio T Ferreira
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

4.  Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease.

Authors:  Marcos A Marques; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

5.  Intranasal Delivery of NEMO-Binding Domain Peptide Prevents Memory Loss in a Mouse Model of Alzheimer's Disease.

Authors:  Suresh B Rangasamy; Grant T Corbett; Avik Roy; Khushbu K Modi; David A Bennett; Elliott J Mufson; Sankar Ghosh; Kalipada Pahan
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 6.  Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease.

Authors:  Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

7.  Immune Suppression of Glia Maturation Factor Reverses Behavioral Impairment, Attenuates Amyloid Plaque Pathology and Neuroinflammation in an Alzheimer's Disease Mouse Model.

Authors:  Mohammad Ejaz Ahmed; Govindhasamy Pushpavathi Selvakumar; Ramasamy Thangavel; Duraisamy Kempuraj; Sudhanshu P Raikwar; Smita Zaheer; Shankar Iyer; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2020-06-05       Impact factor: 4.147

8.  Paeonol Protects Memory after Ischemic Stroke via Inhibiting β-Secretase and Apoptosis.

Authors:  Shan-Yu Su; Chin-Yi Cheng; Tung-Hu Tsai; Ching-Liang Hsieh
Journal:  Evid Based Complement Alternat Med       Date:  2012-03-13       Impact factor: 2.629

9.  Therapeutic approaches to age-associated neurocognitive disorders.

Authors:  R O'Hara; C Derouesné; K N Fountoulakis; J A Yesavage
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

10.  Cinnamon and Its Metabolite Sodium Benzoate Attenuate the Activation of p21rac and Protect Memory and Learning in an Animal Model of Alzheimer's Disease.

Authors:  Khushbu K Modi; Avik Roy; Saurabh Brahmachari; Suresh B Rangasamy; Kalipada Pahan
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.